To research the outcome of IKK2 inhibitor VIII (HY-13060, Medchem Specific, Monmouth Junction, NJ) on OA advancement, MLI surgical procedures were done in 12-7 days-previous C57BL/six WT mice. The mice were injected with IKK2 inhibitor VIII (two?mg/kg, IP) each alternate day for five months. OARSI scoring was done by blinded reviewer determined by